Clinical & Scientific

A breakthrough biomarker, DNlite™, analyzes landmark trial data, offering a new way to identify high-risk diabetes patients missed by current standards.

Visionary Copper and Gold Mines accelerates its Pt. Leamington project, fueled by a major discovery and an ambitious regional strategy in a historic district.

A new study reveals treating advanced gum disease has up to 10x the environmental impact of prevention, reframing sustainability from recycling to daily habits.

A key regulatory win in Japan propels a potential first-ever treatment for Netherton Syndrome, but the real story is the high-wire act of global commercialization.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

A first-in-class drug aims to calm overactive immune cells, offering a new blueprint for treating diseases like rheumatoid arthritis. But can it deliver?

With its first product launch, Daré Bioscience enters a new commercial era. But can a single probiotic launch secure the future of its ambitious pipeline?

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

A new partnership uses healthcare data expertise to guide military caregivers through a mental health crisis. But is this innovative solution enough?

DNV verifies Carbon Ridge’s compact OCCS hits 98% CO2 capture, offering shipowners a viable path to decarbonize existing fleets without major overhauls.

Precision Cardiovascular adds serial entrepreneur Brian Fahey to its board, signaling a push to commercialize its implantable SAW sensor and AI platform.

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?

Stonegate Capital's updated coverage validates AB Science's pivot to ALS and AML, but can its promising clinical assets and shrewd financing de-risk the path forward?

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

Sensorium Therapeutics advances SNTX-2643, a novel anxiety drug, while adding a new CMO and an expert advisory board to guide its clinical journey.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.